GLP-1 medications have been used since 2005 to treat diabetes
Mood changes can drive emotional eating
Diagnosis typically involves physical examination, ultrasound, and fine-needle aspiration biopsy
doi: 10.1016/j.freeradbiomed.2018.01.028 26 KirtoniaASethiGGargM
What CMS is planning to do Through the BALANCE Model, CMS plans to: Work with voluntary GLP-1 manufacturers to establish pricing and access terms Create a standardized pathway for participating Medicaid programs and Medicare plans to cover these medications Pair medication access with lifestyle and nutrition supports grounded in current scientific evidence Evaluate how the model affects access to care, health outcomes, costs and peoples experiences Key dates to know What we dont know yet Several important details have not been finalized, including: When beneficiaries will know whether their state Medicaid program or Medicare plan is participating What the enrollment process will look like The exact clinical criteria for individual eligibility to the programs What lifestyle and nutrition supports will be offered Whether lifestyle and nutrition supports will differ by drug manufacturer Because participation is voluntary for manufacturers and plans, we dont know how many people will participate in the programs An important first step Most people living with obesity who rely on Medicare or Medicaid face barriers to accessing obesity treatments
A: Results vary depending on individual health and adherence, but consistent daily use is typically recommended for at least a few weeks before visible improvements may be experienced
